These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 8595649)

  • 1. Cost-effectiveness analyses of the conversion of patients with non-insulin-dependent diabetes mellitus from glipizide to glyburide and of the accompanying pharmacy follow-up clinic.
    Law AV; Pathak DS; Segraves AM; Weinstein CR; Arneson WH
    Clin Ther; 1995; 17(5):977-87. PubMed ID: 8595649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of glipizide and glyburide in a health maintenance organization.
    Noyes MA; Carter BL; Helling DK; McCormick WC; Ramirez R
    Ann Pharmacother; 1992 Oct; 26(10):1215-20. PubMed ID: 1421641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulary conversion from glipizide to glyburide: a cost-minimization analysis.
    Nadel HL
    Hosp Pharm; 1995 Jun; 30(6):467-9, 472-4. PubMed ID: 10142848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion from glipizide to glyburide: a prospective cost-impact survey.
    Alexis G; Henault R; Sparr HB
    Clin Ther; 1992; 14(3):409-17. PubMed ID: 1638582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycemic control and hypoglycemia in Veterans Health Administration patients converted from glyburide to glipizide.
    Skoff RA; Waterbury NV; Shaw RF; Egge JA; Cantrell M
    J Manag Care Pharm; 2011 Nov; 17(9):664-71. PubMed ID: 22050391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus.
    Ramsdell JW; Braunstein SN; Stephens JM; Bell CF; Botteman MF; Devine ST
    Pharmacoeconomics; 2003; 21(11):819-37. PubMed ID: 12859222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion from glipizide to glyburide: long-term follow-up of a cost-impact survey focusing on the elderly.
    Alexis G; Henault R; Sparr HB
    Clin Ther; 1993; 15(3):607-15. PubMed ID: 8364952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glipizide. A review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus.
    Foster RH; Plosker GL
    Pharmacoeconomics; 2000 Sep; 18(3):289-306. PubMed ID: 11147395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy and potency of long-term therapy with glipizide or glyburide in patients with type 2 diabetes mellitus.
    Kitabchi AE; Kaminska E; Fisher JN; Sherman A; Pitts K; Bush A; Bryer-Ash M
    Am J Med Sci; 2000 Mar; 319(3):143-8. PubMed ID: 10746824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes control in the elderly: a randomized, comparative study of glyburide versus glipizide in non-insulin-dependent diabetes mellitus.
    Rosenstock J; Corrao PJ; Goldberg RB; Kilo C
    Clin Ther; 1993; 15(6):1031-40. PubMed ID: 8111800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
    Diabetes Obes Metab; 2012 Sep; 14(9):803-9. PubMed ID: 22486923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of stress on glycemic control in patients with type II diabetes during glyburide and glipizide therapy.
    Jaber LA; Lewis NJ; Slaughter RL; Neale AV
    J Clin Pharmacol; 1993 Mar; 33(3):239-45. PubMed ID: 8463437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term randomized placebo-controlled double-blind therapeutic comparison of glipizide and glyburide. Glycemic control and insulin secretion during 15 months.
    Birkeland KI; Furuseth K; Melander A; Mowinckel P; Vaaler S
    Diabetes Care; 1994 Jan; 17(1):45-9. PubMed ID: 8112188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents.
    Prendergast BD
    Clin Pharm; 1984; 3(5):473-85. PubMed ID: 6435940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glyburide versus glipizide in the treatment of patients with non-insulin-dependent diabetes mellitus.
    Kilo C; Meenan A; Bloomgarden Z
    Clin Ther; 1992; 14(6):801-12. PubMed ID: 1286487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycemic control was unchanged in Veterans Health Administration patients converted from glyburide to glipizide.
    Aspinall SL; Good CB; Cunningham FE
    J Manag Care Pharm; 2012; 18(1):73. PubMed ID: 22235958
    [No Abstract]   [Full Text] [Related]  

  • 18. A short-term cost-of-treatment model for type 2 diabetes: comparison of glipizide gastrointestinal therapeutic system, metformin, and acarbose.
    Ramsdell JW; Grossman JA; Stephens JM; Botteman MF; Arocho R
    Am J Manag Care; 1999 Aug; 5(8):1007-24. PubMed ID: 10558125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus.
    Burge MR; Schmitz-Fiorentino K; Fischette C; Qualls CR; Schade DS
    JAMA; 1998 Jan; 279(2):137-43. PubMed ID: 9440664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
    Diabetes Care; 2010 Jun; 33(6):1224-9. PubMed ID: 20215447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.